B. Riley Issues Pessimistic Forecast for Lantheus (NASDAQ:LNTH) Stock Price

Lantheus (NASDAQ:LNTH - Get Free Report) had its target price reduced by equities research analysts at B. Riley from $122.00 to $109.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the medical equipment provider's stock. B. Riley's target price would indicate a potential upside of 35.27% from the stock's current price.

Other equities analysts have also issued research reports about the stock. Truist Financial lowered their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $130.50.

Lantheus Stock Performance

LNTH stock traded up $1.39 during trading on Monday, hitting $80.58. 302,662 shares of the company's stock traded hands, compared to its average volume of 1,013,214. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. Lantheus has a 52 week low of $73.11 and a 52 week high of $126.89. The stock has a fifty day moving average price of $86.79 and a two-hundred day moving average price of $91.03. The stock has a market capitalization of $5.58 billion, a price-to-earnings ratio of 22.80 and a beta of 0.11.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The company's quarterly revenue was up .8% on a year-over-year basis. During the same period last year, the firm posted $1.69 earnings per share. As a group, equities analysts anticipate that Lantheus will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director now owns 318,650 shares in the company, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.00% of the company's stock.

Hedge Funds Weigh In On Lantheus

A number of large investors have recently made changes to their positions in LNTH. Summit Securities Group LLC purchased a new position in Lantheus in the fourth quarter valued at about $37,000. Signaturefd LLC lifted its holdings in shares of Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares during the last quarter. Quarry LP grew its stake in shares of Lantheus by 2,350.0% in the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock valued at $48,000 after buying an additional 470 shares in the last quarter. Hughes Financial Services LLC acquired a new position in Lantheus in the first quarter worth approximately $81,000. Finally, Parkside Financial Bank & Trust increased its holdings in Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after buying an additional 280 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.